Superworth

Veracyte price to sales ratio VCYT

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026
6.9×
10-year median
6.1×
Against its 10-year history
60th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.6× to 38.9×
Peer median
5.1×

Veracyte's price to sales ratio is 6.9× as of Oct 23, 2026.

That is above its ten-year median of 6.1×, close to the middle of its last ten years.

Over that time it ranged from 2.6× in Apr 2018 to 38.9× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 5.1×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.9×4.6×8.9×
20256.8×4.0×8.3×
20247.3×4.0×8.0×
20235.9×4.4×6.7×
20226.0×4.2×12.8×
202115.7×13.7×38.9×
202025.1×7.6×29.6×
201912.2×6.7×12.2×
20185.7×2.6×6.8×
20173.1×3.0×4.9×
20163.6×2.6×4.1×
20154.2×3.6×7.8×
20146.4×4.5×17.3×

Against its peers

Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.

CompanyPrice to sales ratio
VCYTVeracyte6.9×
CDNACareDx7.8×
BLLNBillionToOne12.8×
LNTHLantheus4.2×
CAICaris Life Sciences9.1×
BIOBio-Rad Laboratories3.8×
RVTYRevvity6.1×
MEDPMedpace6.7×
LHLabcorp1.9×
DGXQuest Diagnostics2.3×
NRCNRC Health3.5×
Peer median5.1×

Where Veracyte ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Veracyte

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.